Home Promotion Covis concludes promotion and distribution agreement for two

Covis concludes promotion and distribution agreement for two

2
0

GUELPH, Ontario, January 5, 2022 (GLOBE NEWSWIRE) – Covis Pharma Canada Ltd. is pleased to announce that it has entered into an exclusive promotion and distribution agreement with Novartis Pharmaceuticals Canada Inc. (“Novartis”), pursuant to which Covis has been appointed exclusive partner of Novartis to promote and distribute PrSeebri® Breezhaler® and PrUltibro® Breezhaler® in Canada.

Used for the treatment of chronic obstructive pulmonary disease (COPD), these drugs are in addition to Covis’ current Canadian respiratory offering. COPD is a common disease, affecting more than 830,000 people over the age of 35 in Canada in 20201.

“This agreement for the Canadian market, which follows the recent global acquisition of the COPD drugs Tudorza and Duaklir from AstraZeneca, allows us to offer a range of treatment options to Canadians with COPD,” said James Hall, senior and general vice-president of Covis. director for Canada. “Along with Alvesco (ciclesonide) for the treatment of asthma and Omnaris for the treatment of allergic rhinitis, these COPD drugs strengthen our commitment to patients with respiratory disorders and their care providers.

“This agreement with Covis aligns with our goal of providing innovative medicines to improve and transform the lives of patients,” said Andrea Marazzi, Head, Country Pharma Organization, Novartis Pharmaceuticals Canada Inc. “The addition of Seebri® Breezhaler® and Ultibro® Breezhaler® Covis’ portfolio of COPD drugs means more Canadians will benefit.

This agreement for Covis Canada to be the exclusive promotion and distribution partner of Seebri® Breezhaler® and Ultibro® Breezhaler® will come into force on January 1, 2022 and will continue for an initial period of seven years.

About Medication
Seebri® Breezhaler® (glycopyrronium bromide) is a long-acting muscarinic antagonist (LAMA), indicated for long-term maintenance bronchodilator therapy once daily in patients with COPD, including chronic bronchitis and emphysema.

Ultibro® Breezhaler® (indacaterol maleate / glycopyrronium bromide) is a combination therapy that contains both an AMLA and a long-acting beta2-agonist (LABA). It is indicated for the long-term, once-daily maintenance bronchodilator treatment of airway obstruction in patients with COPD), including chronic bronchitis and emphysema, and for the reduction of exacerbations of the airway. COPD in patients with a history of exacerbations.

Both drugs are a dry powder presented as capsules for oral inhalation via the Breezhaler®, a breath-actuated dry powder inhaler.

About Covis
Covis, headquartered in Luxembourg, is a specialist global pharmaceutical company that markets therapeutic solutions for patients with life-threatening illnesses and chronic illnesses.
Additional information is available at www.covispharma.com.
Trademarks are the property of their respective owners.

Media contact
[email protected]

Reference:
1. Statistics Canada. Table 13-10-0096-19. Chronic Obstructive Pulmonary Disease (COPD), 35 years and older. 2021.